shutterstock_1147238582_testing
Testing / Shutterstock.com
31 October 2019Big PharmaSaman Javed

Roche enters $200m hep B treatment collaboration

Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
23 July 2019   The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Big Pharma
7 November 2019   The US Court of Appeals for the Second Circuit has dismissed a Russian pharmaceutical company’s antitrust claims against Roche.
Americas
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.

More on this story

Big Pharma
23 July 2019   The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Big Pharma
7 November 2019   The US Court of Appeals for the Second Circuit has dismissed a Russian pharmaceutical company’s antitrust claims against Roche.
Americas
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.

More on this story

Big Pharma
23 July 2019   The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Big Pharma
7 November 2019   The US Court of Appeals for the Second Circuit has dismissed a Russian pharmaceutical company’s antitrust claims against Roche.
Americas
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.